Ken Research announced its latest publication on “Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market” provides a comprehensive analysis of the glaucoma treatment drugs market. The report includes the market share contributed by the sales of generic and patented drugs globally for treatment of glaucoma. Further, the market in the study is differentiated by various parameters such as drug classes which include prostaglandin analogues, alpha agonist, beta blockers, carbonic Anhydrase inhibitors, cholinergic, and combined medications. On the basis of formulation, glaucoma treatment drugs market is categorized into topical eye drops, semisolid dosage forms and pills. The market is also segmented by six geographical regions across the globe – North America, Europe, Asia Pacific, Middle East, Latin America, and Rest of the World.
Detailed snapshot on key regions of the market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail. The study also highlights the detailed information about major drug manufacturers in the global glaucoma treatment drugs market and their respective shares by revenue in 2015. Analysis on pipeline products, patented drugs available in the market, and difference between generic and patented drugs is provided in the report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter’s five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global glaucoma treatment drugs market has also been discussed along with recommendations from analyst view.

Global Glaucoma Treatment Drugs Market
Glaucoma being the second common cause of blindness globally has emerged as a worldwide problem. It was estimated that approximately ~ million people were affected with glaucoma worldwide in year 2013. The statistics clearly advocates the high demand for glaucoma treatment drugs across the globe. It has been estimated that glaucoma treatment drugs generated USD ~ million of revenue in 2010. However, the revenue declined at a high rate till 2013, owing to the expiry of major patented drugs including ~ and ~. Although as a result of increasing prevalence of glaucoma, the market experienced steady growth afterwards and the market was valued at USD ~ million in 2015. Aging population and rising awareness in the emerging economies owing to the efforts of the government and NGOs were the major reasons which assisted the market in its growth during this period.
Glaucoma Treatment Drugs Market Segmentation
On the basis of drug class, Prostaglandin analogues dominated the glaucoma treatment drugs market with revenue share of ~% in 2015 owing to its efficacy to treat glaucoma and presence of two high revenue generating patented drugs including Travatan Z and Lumigan. Additionally, high sales of off-patent drug Xalatan also help the segment in generating high revenue. Beta blockers with revenue share of ~% in 2015 followed prostaglandin analogues majorly due to high preference for these drugs in India and China.
By geographical regions, North America dominated the market with revenue share of ~% in 2015. High prevalence of glaucoma, high awareness among people and economic stability to undergo expensive treatment options are the major factors which have driven the glaucoma treatment drugs market in North America. Approximately ~ million people in the US were affected from glaucoma in 2015. Low cost of the drugs in Europe with strong reimbursement and high presence of patient pool in Asia Pacific regions helped these respective regions capture second and third position in the global glaucoma treatment drugs market. Europe captured ~% share, by revenue followed by Asia Pacific with revenue share of ~% in the global market in 2015.

Generic versus Branded Glaucoma Drugs
Glaucoma being a highly prevalent disease demands for effective and affordable treatment options. The launch of generic drugs in the market during the historical period, especially of ~ has resulted in decline in revenue share of patented drugs in the market from ~% in 2010 to % in 2015. Low cost of generic drugs is the major factor which has resulted in high adoption of generic drugs in the market. It has been observed that branded drugs cost approximately five times that of generic drugs. However, low efficacy of generic drugs restricts the ophthalmologists in prescribing generic drugs over patented drugs in economically stable countries. It has been noted that generic drugs show diverse bioequivalence with change in temperature. In addition to this bottle’s material, shape, and size, delivery dose drop size, and different pH also impacts the efficacy of generic drug, resulting in more number of side effects and higher time frame treatment.

Competitive Scenario
Alcon dominated the glaucoma treatment drugs market in 2015 with revenue share of ~% owing to its wide range of products in its portfolio and high demand for its two patented drugs Simbrinza and Travatan Z. Allergan followed Alcon with revenue share of ~% in 2015. Wide distribution network in addition to patented product portfolio including Lumigan and Alphagen/Combigan assisted Allergan in gaining second position in the market. Pfizer Inc. and Akorn Inc. captured third and fourth position in the market respectively. High sales of off-patent drug Xalatan helped Pfizer in attaining respective position in the market.

Key Topics Covered in the Report:
The market size of Global Glaucoma Treatment Drugs Market
Market segmentation of Global Glaucoma Treatment Drugs Market on the basis of Drug Class, Formulations, and Geographical Analysis
Snapshot on North America Glaucoma Treatment Drugs Market
Snapshot on Europe Glaucoma Treatment Drugs Market
Snapshot on Asia Pacific Glaucoma Treatment Drugs Market
Porter’s Five Forces Analysis for Global Glaucoma Treatment Drugs Market
Trends and Developments in Global Glaucoma Treatment Drugs Market
Snapshot on Patented Glaucoma Treatment Drugs Market
Generic Versus Branded Glaucoma Drugs
Pipeline Analysis of Global Glaucoma Treatment Drugs Market
Competitive Landscape and Detailed Company Profiles of the Major Market Players
Future Outlook and Projections of Global Glaucoma Treatment Drugs Market
Analyst Recommendations
Macro-Economic Factors Impacting the Global Glaucoma Treatment Drugs Market



For more coverage click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/global-glaucoma-treatment-drugs-market-statistics/47381-91.html
Related Reports:
• Asia Oncology Drug Market Outlook to 2019 - Driven by Rising Demand and Intensifying Joint Ventures between Companies
• The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth
• India Hearing Impairment Market Outlook To 2018 - Upsurging Demand for Hearing Care Devices
Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
[email protected]
+91-9015378249